Company Overview and News

0
Pidilite Industries Limited - Press Release

2018-07-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PIDILITIND PDLTY 500331

0
Pidilite opens new adhesive manufacturing plant in Polgahawela

2018-07-11 lankabusinessonline
Jul 11, 2018 (LBO) – A state-of-the-art manufacturing plant of Pidilite Lanka (Private) Limited was formally commissioned at Polgahawela in Sri Lanka’s North Western Province, recently.
PIDILITIND PDLTY 500331

1
Q1 Results 2018: What to expect

2018-07-08 livemint
Mumbai: Listed companies, barring telecom firms and select banks, are expected to post decent earnings growth in the June quarter (Q1), helped by rising consumption and the low base of last year, various broking companies said. The falling rupee has helped exporters as well.
500825 500820 509480 DABUR BRTQY HINDUNILVR ASIANPAINT DBRQY 532215 EQMNY 500096 PIDILITIND 532187 PDLTY AXISBANK 500696 HDFCBANK 500790 BRITANNIA NSZTY 500331 BERGEPAINT AXB INDUSINDBK IBN NESTLEIND AXBKY AXBA ICICIBANK 532210 HDB 532174 500180 CUB

0
Pidilite Industries Limited - Trading Window

2018-06-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PIDILITIND PDLTY 500331

0
Pidilite Industries Limited - Investor Presentation

2018-06-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PIDILITIND PDLTY 500331

17
MFs offloaded shares in PowerGrid, InterGlobe Aviation in May

2018-06-20 thehindubusinessline
Suresh P Iyengar The mutual fund industry has offloaded 22 per cent of Power Grid Corporation shares worth ₹1,905 crore in May, as prospects of the company looked bleak with no major new power project being launched and a sharp decline in power generation.
RIFS 532617 HCTHY TTQQY TATACHEM 500390 PIDILITIND PDLTY 532281 HDFCBANK 500770 500331 INDIGO RELEY IBN RELFF JETAIRWAYS 535322 REPCOHOME 539448 RELINFRA ICICIBANK HDB 532174 500180 HCLTECH RIFA 534809 PCJEWELLER

0
Pidilite Industries Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-06-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PIDILITIND PDLTY 500331

0
Pidilite Industries Limited - Updates

2018-06-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PIDILITIND PDLTY 500331

0
Pidilite Industries Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-06-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PIDILITIND PDLTY 500331

0
Pidilite Q4 Result: Basking in GST glory, but input cost inflation a spoilsport

2018-05-31 livemint
The Pidilite Industries Ltd stock touched a 52-week high of Rs1,195.40 on Wednesday after it reported March quarter earnings that beat analysts’ expectations.
PIDILITIND PDLTY 500331

0
PIDILITE Industries Ltd. ADR 2018 Q4 - Results - Earnings Call Slides

2018-05-29 seekingalpha
The following slide deck was published by PIDILITE Industries Ltd. ADR in conjunction with their 2018 Q4 earnings call.
PIDILITIND PDLTY 500331

0
Pidilite Industries Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PIDILITIND PDLTY 500331

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 00B0JJV59